in particular, experimental autoimmune encephalomyelitis (EAE), and cuprizone-induced demyelination models are widely used ( 01 , in EAE mice has been documented ( 3.2 Other Demyelinating Disorders As far as we searched, no studies have ever tried to investigate the potential efficacy of GLP-1RAs for demyelinating disorders other than MS (GuillainBarr syndrome, CIDP, combined central, and peripheral demyelination, etc
Orforglipron is currently only available in the context of clinical and laboratory trials, and the estimated price of the formulation is more than US$300 per month for 60 10mg capsules
Lippincott Williams & Wilkins Publishs
Buprenorphine alone does not treat it
Alternatives if the Mexico route does not work for you
None examined cognitive endpoints